Zhengye Biotechnology Holding Ltd
ZYBT evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for ZYBT—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ZYBT
Zhengye Biotechnology Holding Ltd (ZYBT) is a China-based animal health company focused on developing and commercializing veterinary vaccines, with a recently approved Mycoplasma Bovis Live Vaccine and ongoing expansion into domestic and international markets.
Key risk: Dependence on swine vaccine demand
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
$82.0M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Dec 31, 2025.
Zhengye Biotechnology Holding Ltd (ZYBT) is a China-based animal health company focused on developing and commercializing veterinary vaccines, with a recently approved Mycoplasma Bovis Live Vaccine and ongoing expansion into domestic and international markets.
- Cash and equivalents of $7.2M as of 2025-12-31 [sec].
- Total revenue of $16.6M and net loss of -$10.0M for the fiscal year ended 2025-12-31 [sec].
- Obtained a Registration Certificate of New Veterinary Drugs for the Mycoplasma Bovis Live Vaccine (HB150 strain) on February 25, 2025, and a production approval number on July 23, 2025 [sec · filed 2026-04-28].
- Expanding into overseas markets including Egypt, Pakistan, Vietnam, and planning for Africa, Central Asia, and West Asia [sec · filed 2026-04-28].
- Established a new domestic subsidiary, Beijing Zhongnong Zhengye Biotechnology Co., Ltd., to integrate sales, technical services, and marketing [sec · filed 2026-04-28].
What works
- The company has a recently approved new veterinary drug (Mycoplasma Bovis Live Vaccine) that received both a registration certificate and production approval in 2025, indicating progress in product development [sec · filed 2026-04-28].
- The company is actively expanding its geographic reach into multiple international markets (Egypt, Pakistan, Vietnam, and planning for Africa, Central Asia, West Asia), which could diversify revenue sources [sec · filed 2026-04-28].
- The company has a pipeline of products in development, including a pentavalent inactivated vaccine, suggesting ongoing R&D efforts [sec · filed 2026-04-28].
What to weigh
- The company reported a net loss of -$10.0M for the fiscal year ended 2025-12-31, indicating current lack of profitability [sec].
- The company's business is heavily dependent on swine vaccines, and any reduction in demand for swine vaccines could adversely affect its financial condition [sec · filed 2026-04-28].
- The company's product development pipeline includes early-stage candidates that require significant additional development and clinical testing, which is costly and time-consuming with no guarantee of success [sec · filed 2026-04-28].
- The company relies on third-party collaborators, licensees, and partners for research, development, and commercialization, creating dependency risks [sec · filed 2026-04-28].
From the filings
Quoted directly from source documents.
The company obtained a Registration Certificate of New Veterinary Drugs for the Mycoplasma Bovis Live Vaccine (HB150 strain) in February 2025.
“the operating entity obtained a Registration Certificate of New Veterinary Drugs for the Mycoplasma Bovis Live Vaccine (HB150 strain) on February 25, 2025”
SEC filings · April 28, 2026
The company is expanding into overseas markets such as Egypt, Pakistan, and Vietnam.
“The operating entity has expanded its business in Egypt, Pakistan, and Vietnam, and is planning to expand into overseas markets such as Africa, Central Asia, and West Asia.”
SEC filings · April 28, 2026
The company has a pentavalent inactivated vaccine candidate that has not yet undergone a clinical trial.
“the operating entity obtained a Registration Certificate of New Veterinary Drugs for the Pentavalent Inactivated Vaccine for C”
SEC filings · April 28, 2026
The company's cash and equivalents were $7.2 million as of December 31, 2025.
“US$7.2 million”
SEC filings · April 28, 2026
Risks & what to watch (4)›
Key risks
- Dependence on swine vaccine demand — Any reduction in demand for swine vaccines could adversely affect the company's business, financial condition, and results of operations [sec · filed 2026-04-28].
- Clinical trial and regulatory delays — The company's product candidates require costly and time-consuming clinical trials and regulatory approvals; delays or failures could harm commercialization [sec · filed 2026-04-28].
- Reliance on third-party partners — The company depends on collaborators, licensees, and other third parties for R&D, testing, and commercialization; poor performance by partners could materially harm the business [sec · filed 2026-04-28].
- Historical growth may not be sustainable — The company's historical growth rates and performance may not be indicative of future growth or financial results [sec · filed 2026-04-28].
What to watch
- Progress of clinical trials for the pentavalent inactivated vaccine and other pipeline candidates [sec · filed 2026-04-28].
- Revenue growth and path to profitability given the recent net loss of -$10.0M [sec].
- Expansion into new international markets (Africa, Central Asia, West Asia) and domestic market through the new subsidiary [sec · filed 2026-04-28].
- Ability to maintain cash runway of $7.2M as of 2025-12-31 while funding R&D and operations [sec].
Sources: SEC filings · Generated August 11, 2026 · How we verify sources →
Run Zhengye Biotechnology Holding Ltd through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Zhengye Biotechnology Holding Ltd facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
Profitable (positive operating cash flow)
D/E 0.52 · 0% dilution
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
5
Total value held
$101K
| Holder | Shares | Value |
|---|---|---|
| xtx topco ltd | 44,146 | $41K |
| winton group ltd | 33,389 | $31K |
| geode capital management, llc | 29,068 | $27K |
| royal bank of canada | 1,230 | $1K |
| morgan stanley | 261 | $244 |
Short Interest
as of Apr 21, 2026- % of float
- 3.3%
- Days to cover
- 0.3
- Shares short
- 147,787
- Daily short volume (Jul 17, 2026)
- 1.8%
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ZYBT short interestFrequently asked questions
What is the AI investment thesis for Zhengye Biotechnology Holding Ltd?
Zhengye Biotechnology Holding Ltd (ZYBT) is a China-based animal health company focused on developing and commercializing veterinary vaccines, with a recently approved Mycoplasma Bovis Live Vaccine and ongoing expansion into domestic and international markets.
Who is the CEO of Zhengye Biotechnology Holding Ltd?
Mr. Songlin Song is the chief executive officer of Zhengye Biotechnology Holding Ltd (ZYBT).
Where is Zhengye Biotechnology Holding Ltd headquartered?
Zhengye Biotechnology Holding Ltd (ZYBT) is headquartered in Jilin, China.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.